Jul 28, 2025
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Jun 10, 2025
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
May 28, 2025
Alamar Biosciences joins forces with SciLifeLab to advance understanding of human disease
May 15, 2025
Alamar Biosciences Expands NULISAseq(TM) CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Mar 24, 2025
Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120
Feb 20, 2025
Alamar Biosciences Launches Certified Service Provider Program to Expand Access to NULISA technology for Academic and Biopharmaceutical Researchers
Jan 22, 2025
Alamar Biosciences Unveils NULISAseq Inflammation Panel AQ
Dec 05, 2024
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
Nov 19, 2024
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays
Jul 30, 2024
Alamar Biosciences Establishes European Headquarters and Distribution Center in Milan, Italy
Jul 25, 2024
Alamar Biosciences Achieves ISO 13485 Certification, Demonstrating its Commitment to Quality and Safety
Jun 27, 2024
Alamar Biosciences and Biomarkers of Aging Consortium Join Forces to Revolutionize Longevity Research
Apr 04, 2024
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Mar 05, 2024
Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq(TM) CNS Disease Panel 120 and NULISAqpcr(TM) pTau-217 Assays
Feb 26, 2024
Alamar Biosciences Raises $128 Million in Oversubscribed Series C Financing to Accelerate Commercialization of its Proteomics Platform
Jan 04, 2024
Alamar Biosciences Announces Commercial Launch of the ARGO(TM) HT System and the NULISAseq(TM) Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids